Matinas BioPharma Board Approves 1-For-15 Reverse Stock Split Effective September 28, 2026
Matinas BioPharma Holdings Inc MTNB
$0.16
▼ -10.11%
($-0.02)
⬇️ Below Yest. Low
Open
$0.17
Prev Close
$0.18
Day Range
$0.15 – $0.18
52W Range
$0.15 – $2.02
Market Cap
$2.35M
Beta
2.19
EPS (TTM)
$-1.62
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2014-06-03 |
| Shares Out. | 13,690,000 |
| Website | matinasbiopharma.com/ ↗ |
| Phone | 13026365400 |
| Employees | 2 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.3M |
| Free Cash Flow | -$6.4M |
| Total Assets | $3.4M |
| Total Liabilities | $1.6M |
| Equity | $1.8M |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
Matinas BioPharma Holdings Inc is a publicly traded company under the ticker symbol MTNB on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-10-01)